About PROMETHERA^® Biosciences

Promethera^® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.

Promethera^® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.

Promethera^® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

• Promethera^® HepaStem, a unique cell therapy product, to treat severe diseases of the liver affecting children and adults.
• Promethera^® HepaScreen, a cell model designed for the discovery and pre-clinical evaluation of new chemical entities.

Promethera^® Biosciences was founded in 2009 by Sopartec SA, the technology transfer company for the Université Catholique de Louvain and Professor Etienne Sokal, a leading expert in hepatology and cell therapy. In May 2009, Eric Halioua became the Chief Executive Officer of Promethera^® Biosciences.

End of October 2009, Promethera^® Biosciences has completed a 5.3 million euros A-round of funding. The round has been completed by more than 4 million euros of grants and loans from the Walloon Region.